Prognostic value of metabolic parameters determined by preoperative $^{18}$F-FDG PET/CT in patients with uterine carcinosarcoma

Hyun Ju Lee,1 Jong Jin Lee,2 Jeong-Yeol Park,1 Jong-Hyeok Kim,1 Yong-Man Kim,1 Young-Tak Kim,1 Joo-Hyun Nam1

1Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
2Department of Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

ABSTRACT

Objective: To evaluate the prognostic value of metabolic parameters measured by preoperative $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography (PET)/computed tomography (CT) in patients with uterine carcinosarcoma (UCS). Methods: Data of 55 eligible patients with UCS who underwent preoperative $^{18}$F-FDG PET/CT and surgical staging were analyzed retrospectively. Maximum standardized uptake value ($SUV_{max}$), metabolic tumor volume ($MTV_{2.5}$), and total lesion glycolysis ($TLG_{2.5}$) of the primary tumors were measured using a $SUV_{max}$ threshold of 2.5. The optimal cutoff value of each parameter was determined by time-dependent receiver operating characteristic curve, and its impact on progression-free survival and overall survival was evaluated by Cox proportional hazards model. Results: During a median follow-up period of 29 (range, 1.5–109.4) months, 47.3% (26/55) of the patients experienced disease progression, and the disease-associated mortality rate was 43.6% (24/55). Univariate analysis determined that hazard ratios (HRs) for disease progression for $SUV_{max}$ (≥8.33), $MTV_{2.5}$ (≥63.92 mL), and $TLG_{2.5}$ (≥396.16) were 1.930 (95% confidence interval [CI]=0.793–4.701), 3.264 (95% CI=1.466–7.268), and 2.692 (95% CI=1.224–5.924), respectively. And, HRs for death were 1.979 (95% CI=0.774–5.060), 2.764 (95% CI=1.217–6.274), and 2.721 (95% CI=1.198–6.182), respectively. While peritoneal cytology, histology, and tumor diameter were independent prognostic factors in multivariate analysis, MTV and TLG were not. Conclusion: Though MTV and TLG of primary UCS were not independent predictors compared to surgically obtained data, MTV and TLG of primary UCS may provide useful information on prognosis especially in patients who are not able to undergo surgical staging. Keywords: Carcinosarcoma; Fluorodeoxyglucose F18; Positron Emission Tomography Computed Tomography; Standardized Uptake Value; Metabolic Tumor Volume; Total Lesion Glycolysis

INTRODUCTION

Uterine carcinosarcoma (UCS), also known as uterine malignant mixed Müllerian tumor, is a biphasic uterine malignancy comprising epithelial and mesenchymal elements. It has recently been categorized as a high-grade endometrial cancer, and most UCSs...
may arise from a monoclonal cell undergoing epithelial-to-mesenchymal metaplastic transformation [1-3]. While UCS is extremely rare, having an incidence rate of 2/100,000 females and comprising <5% of all uterine malignancies, it behaves more aggressively and is associated with poorer outcomes than high-grade endometrioid endometrial cancer [4-7]. Approximately 60% of all patients with UCS present with extraterine disease; further, 33%–55% of UCSs recur within 2 years of diagnosis, and the estimated 5-year survival rate is 20%–35% [4,8,9].

In a few retrospective studies, prognostic factors associated with recurrence and mortality rates of UCS are inconsistent and include cancer antigen 125 (CA-125) level, performance status, the International Federation of Gynecology and Obstetrics (FIGO) stage, myometrial invasion, lymphovascular space invasion, adnexal and serosal involvement, peritoneal cytology, pelvic lymphadenectomy, adjuvant therapy, and presence of a residual tumor of >1 cm [6,8,10,11]. However, most of these prognostic factors can be assessed only by extensive surgical procedures. Preoperative noninvasive imaging modalities that can be used to identify high-risk patients with UCS would be useful for planning appropriate therapeutic strategies and predicting prognosis before surgery while avoiding comprehensive surgical procedures, particularly in patients with severe comorbidities or at high risks of postoperative complications. Further, such modalities would contribute to improved outcomes in patients with UCS [12-14].

Among the currently available preoperative diagnostic tools, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) enables identification of an abnormal biological activity of cancer tissue based on 18F-FDG uptake. The maximum standardized uptake value (SUV\text{max}) measured by 18F-FDG PET/CT, reflecting tumor aggressiveness, may be a predictor of poor prognosis in numerous malignancies [12]. Although primary UCS exhibits increased 18F-FDG uptake, similar to that exhibited in other endometrial cancers, the relationship between metabolic parameters measured by 18F-FDG PET/CT and oncological outcomes has rarely been studied [15,16]. Our primary aim was to evaluate the prognostic value of metabolic parameters measured by 18F-FDG PET/CT in predicting the oncological outcomes of patients with UCSs.

**MATERIALS AND METHODS**

1. **Patient population**

Eighty-five patients were newly diagnosed with UCS at Asan Medical Center between September 2006 and May 2015, and 60 patients underwent preoperative 18F-FDG PET/CT and surgical staging. Among them, 5 patients who showed no residual tumor in a hysterectomy specimen after endometrial biopsy (n=3) or immeasurable SUV\text{max} on 18F-FDG PET/CT (n=1), or who underwent incomplete surgical procedure (n=1) were excluded, and the data of 55 patients were analyzed retrospectively. No patient received neoadjuvant chemotherapy or preoperative radiotherapy or had other malignancies or underlying diseases that could affect survival. The present study overlapped in subjects (52/55) from our prior publication [17]. Demographic and clinicopathological characteristics and survival data were obtained from the patients’ medical records and surgical pathology report. This study protocol was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea; the need for obtaining informed consent was waived.
2. PET/CT scanning procedures

According to hospital’s management strategy, $^{18}$F-FDG PET/CT has been recommended for preoperative evaluation of UCS. Therefore, $^{18}$F-FDG PET/CT was performed in most patients except those who refused the recommendation. Patients were instructed to avoid strenuous exercise for 24 hours before $^{18}$F-FDG PET/CT to minimize radiotracer uptake by the muscle. They were also instructed to fast for at least 6 hours prior to $^{18}$F-FDG injection. Venous blood glucose levels were controlled to stay <150 mg/dL. Following injection with 370–555 MBq (10–15 mCi) of $^{18}$F-FDG, patients were allowed to rest in the sitting or supine position for 60 minutes prior to scanning. Thereafter, they were positioned in the scanner with their arms above their heads. Skull base-to-mid thigh PET/CT scans from both the upper thighs to the head were performed using the Discovery STE, Discovery PET/CT 710, Discovery PET/CT 690, and Discovery PET/CT 690 Elite (GE Healthcare, Waukesha, WI, USA) and Biograph TruePoint 16 and Biograph TruePoint 40 (Siemens Healthcare, Erlangen, Germany) scanners. The devices combined multislice CTs with PET scans, and CT data were used for attenuation correction. Totally, 5–6 bed positions with 2–3 minutes per position were acquired. Calibration of each scanner against dose calibrators and well counters was routinely performed. The measured SUV in the phantom background was within the acceptable range of 90%–110%.

3. Imaging interpretation

SUV was calculated using the formula; SUV = concentration of radioactivity in volume of interest (VOI) (MBq/mL) × lean body weight/injected radioactivity (g/MBq). Metabolic parameters including SUV$_{\text{max}}$, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured by a board certified nuclear medicine physician with 14 years of PET experience who was blinded to patient information. Implanted software packages were used to measure metabolic parameters (Advantage Workstation, GE Healthcare, or TrueD, Siemens Healthcare). Primary tumor boundaries were delineated using SUV thresholds of 2.5 and 3.0 [18,19]. VOIs were drawn to include the entire UCS. MTV$_{2.5}$ and MTV$_{3.0}$ were defined as the sum of voxel volumes with SUV of ≥2.5 and ≥3.0 within a given VOI, respectively. TLG$_{2.5}$ and TLG$_{3.0}$ were calculated as MTV$_{2.5}$ and MTV$_{3.0}$ multiplied by the average SUV of voxels, respectively. In patients where the tumor had no hypermetabolic activity above the SUV threshold within the uterus, MTV and TLG of the primary tumor were considered as zero. All VOIs were checked slice by slice on transaxial and coronal planes to check whether the physiologic uptake of bowel and ovary or urine activity included. When the physiologic uptakes were included, region of interest (ROI) were manually drawn slice by slice and MTV were calculated again within the predefined sum of ROIs.

4. Surgical staging and subsequent treatment

Endometrial biopsy with cervical dilatation and endometrial curettage was performed to identify endometrial pathology prior to surgical staging. After preoperative evaluation including $^{18}$F-FDG PET/CT, patients underwent surgery for FIGO staging. Surgical procedures included simple or radical hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic and/or para-aortic lymph node (LN) dissection, exploration of the peritoneal cavity, peritoneal washing cytology, resection of other involved organs, and biopsy of any suspicious areas through laparotomy or laparoscopy. All surgical specimens were examined by experienced pathologists. Patients received adjuvant therapy depending on their FIGO stage, histopathology, and preference and at the treating physician’s discretion. Routine surveillance was subsequently performed by a gynecological oncologist according to our institution’s protocol.
5. Statistical analysis

Progression-free survival (PFS) was the time from surgical staging to the first instance of any clinical or imaging finding suggestive of disease progression or death from any cause. Overall survival (OS) was the time between surgical staging and death or the most recent follow-up. The clinicopathological features and metabolic parameters of $^{18}$F-FDG PET/CT were used as variables. Time-dependent receiver operating characteristic (ROC) curves were generated to determine optimal cutoff values of metabolic parameters using the Maxstat package, a maximal $\chi^2$ method in R (version 3.2.2; R development Core Team, Vienna, Austria, http://www.R-project.org). Univariate Cox proportional hazards model was used to evaluate both continuous and categorical variables, and estimated hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Multivariate Cox proportional hazards model with backward elimination method was used to assess the potential independent effects of prognostic factors for PFS or OS. Student’s t-test or Mann-Whitney U test was used to compare means or mean ranks of metabolic parameters between groups. Kaplan-Meier and log-rank tests were used for survival analyses. A 2-sided p-value of <0.05 was considered statistically significant for all analyses. Statistical analyses were performed using SPSS 21.0 software for Windows (IBM, Armonk, NY, USA).

RESULTS

1. Patient characteristics and treatment outcomes

Among 55 patients, 44 patients (80.0%) had UCS in both endometrial biopsy and hysterectomy specimens, and the rest showed different histologic findings in endometrial biopsy specimens. The median age at diagnosis was 60 (range, 40–77) years. The percentage of patients with FIGO stage I, II, III, and IV disease was 36.4% (20/55), 7.3% (4/55), 40.0% (22/55), and 16.4% (9/55), respectively. The median preoperative CA-125 level was 25 (2.5–825) U/mL, and the median maximum uterine tumor diameter was 6.0 (1.0–18.0) cm. Heterologous UCS, deep myometrial invasion (≥50%), lymphovascular space invasion, cervical stromal invasion, adnexal invasion, and malignant peritoneal cytology were found in 43.6% (24/55), 54.5% (30/55), 45.5% (25/55), 41.8% (23/55), 27.3% (15/55), and 29.1% (16/55) of the patients. The median $\text{SUV}_{\text{max}}$, $\text{MTV}_{2.5}$, and $\text{TLG}_{2.5}$ of the primary UCS were 8.8 (2.1–26.7), 43.8 (0–923.0) mL, and 191.6 (0–3,050.2) g, respectively. $\text{SUV}_{\text{max}}$ of ≤2.5 and ≤3.0 were detected in 1 and 3 patients, respectively, whose corresponding MTV and TLG values were zero. The median interval between $^{18}$F-FDG PET/CT and surgical staging was 7 (1–25) days. Pelvic or para-aortic LN metastasis was confirmed in 43.6% (24/55) of the patients. Adjuvant therapy was performed in 83.6% (46/55) of the patients and included adjuvant chemotherapy (63.6%, 35/55), radiotherapy (3.6%, 2/55), and concurrent chemoradiation (16.4%, 9/55). During a median follow-up period of 29 (1.5–109.4) months, 47.3% (26/55) of the patients experienced disease progression and 43.6% (24/55) died from UCS. The median and mean PFS were 16.5 (0.5–109.4) and 32.0±4.2 months, respectively. The median and mean OS were 25.6 (1.5–109.4) and 37.5±4.3 months, respectively. Other clinicopathological characteristics of the patients are listed in Table 1.

2. Cutoff values of metabolic parameters as predictors of disease progression and death

Using the time-dependent ROC curve for primary tumors, optimal cutoff values for predicting 3-year disease progression were 8.33 (area under the curve [AUC]=0.541; sensitivity, 75.4%; specificity, 49.5%), 63.92 mL (AUC=0.755; sensitivity, 66.2%; specificity,
Table 1. Patients’ characteristics (n=55)

| Characteristics                  | Values       | Percentage (%) |
|----------------------------------|--------------|----------------|
| Age (yr)                         | Median (range) | 60 (40–77)     |
| BMI (kg/m²)                      | Median (range) | 24 (17–36)     |
| Postmenopause                    | 52           | 94.5           |
| Parity                           |              |                |
| 0                                | 3            | 5.5            |
| 1                                | 2            | 3.6            |
| ≥2                               | 50           | 90.9           |
| Preoperative CA-125 (U/mL)       | Median (range) | 25 (2.5–925.0) |
| Tumor diameter (cm)              | Median (range) | 6.0 (1.0–18.0) |
| FIGO stage                       |              |                |
| I                                | 20           | 36.4           |
| II                               | 4            | 7.3            |
| III                              | 22           | 40.0           |
| IV                               | 9            | 16.4           |
| Histology                        |              |                |
| Homologous                       | 31           | 56.4           |
| Heterologous                     | 24           | 43.6           |
| Myometrial invasion              |              |                |
| <50%                             | 25           | 45.5           |
| ≥50%                             | 30           | 54.5           |
| Lymphovascular space invasion    |              |                |
| 25                               | 45.5         |
| Cervical stromal invasion        | 23           | 41.8           |
| Adnexal invasion                 | 15           | 27.3           |
| Performed surgical procedure     |              |                |
| TAH                              | 35           | 63.6           |
| LAVH                             | 16           | 29.1           |
| RH                               | 4            | 7.3            |
| BSO                              | 55           | 100.0          |
| PALND                            | 43           | 78.2           |
| PLND                             | 54           | 98.2           |
| Omentectomy                      | 34           | 61.8           |
| Pelvic or para-aortic LN metastases | 24           | 43.6           |
| Adjuvant treatment               |              |                |
| None                             | 9            | 16.4           |
| Chemotherapy                     | 35           | 63.6           |
| Radiotherapy                     | 2            | 3.6            |
| Concurrent chemoradiation        | 9            | 16.4           |
| Primary tumor ¹⁸F-FDG PET/CT feature | Median (range) | 8.8 (2.1–26.7) |
| SUVmax                          |              |                |
| MTV<sub>2.5</sub> (mL)          | 43.8 (0–923) |
| TLG<sub>2.5</sub> (g)           | 191.6 (0–3,050.2) |
| MTV<sub>3.0</sub> (mL)          | 31.7 (0–542) |
| TLG<sub>3.0</sub> (g)           | 157.8 (0–2,836.9) |
| Progression                     | 26           | 47.3           |
| Death                            | 24           | 43.6           |
| PFS (mo)                         | Median (range) | 16.5 (0.5–109.4) |
| OS (mo)                          | Median (range) | 25.6 (1.5–109.4) |

¹⁸F-FDG, ¹⁸F-fluorodeoxyglucose; BMI, body mass index; BSO, bilateral salpingo-oophorectomy; CA-125, cancer antigen 125; CT, computed tomography; FIGO, International Federation of Gynecology and Obstetrics; LAVH, laparoscopic-assisted vaginal hysterectomy; LN, lymph node; MTV, metabolic tumor volume; OS, overall survival; PALND, para-aortic lymph node dissection; PET, positron emission tomography; PFS, progression-free survival; PLND, pelvic lymph node dissection; RH, radical hysterectomy; SUV<sub>max</sub>, maximum standardized uptake value; TAH, total abdominal hysterectomy; TLG, total lesion glycolysis.

*MTV<sub>2.5</sub> and TLG<sub>2.5</sub> were considered as zero in 1 patient with SUV<sub>max</sub> of 2.11; *MTV<sub>3.0</sub> and TLG<sub>3.0</sub> were considered as zero in 3 patients with SUV<sub>max</sub> of 2.11, 2.86, and 2.97, respectively.

85%), and 396.16 g (AUC=0.747; sensitivity, 64.4%; specificity, 83.5%) for SUV<sub>max</sub>, MTV<sub>2.5</sub>, and TLG<sub>2.5</sub>, respectively. Optimal cutoff values for predicting the 3-year death were 8.33 (AUC=0.584; sensitivity, 77.7%; specificity, 51.2%), 63.92 mL (AUC=0.726; sensitivity, 62%; specificity, 81.2%), and 396.16 g (AUC=0.724; sensitivity, 61.7%; specificity, 81%) for SUV<sub>max</sub>, MTV<sub>3.0</sub>, and TLG<sub>3.0</sub>, respectively (Table 2, Fig. 1). AUCs and optimal cutoff values of MTV<sub>3.0</sub> and TLG<sub>3.0</sub> were also calculated (Table 2, Supplementary Fig. 1).
Table 3 summarizes the prognostic value of clinicopathological and metabolic parameters. Optimal cutoff values of tumor size for predicting 3-year disease progression and 3-year death were calculated as 5.5 cm (AUC=0.821; 95% CI=0.695–0.946; sensitivity, 87.3%; specificity, 72.6%) and 6.5 cm (AUC=0.784; 95% CI=0.647–0.920; sensitivity, 68.6%; specificity, 85.0%), respectively, and we used the mean value (6 cm) of them for the categorical data analysis. Among the clinicopathological variables, FIGO stage III–IV, tumor diameter of ≥6 cm, heterologous histology, deep myometrial invasion, cervical stromal invasion, adnexal invasion, and malignant peritoneal cytology were significant prognostic factors for both PFS and OS by univariate Cox proportional hazards analysis. The presence of pelvic or para-aortic LN metastasis was a significant prognostic factor for only PFS. The analysis of metabolic parameters as continuous variables determined that SUV\textsubscript{max} (p=0.873), MTV\textsubscript{2.5} (p=0.070), MTV\textsubscript{3.0} (p=0.873), TLG\textsubscript{2.5} (p=0.873), TLG\textsubscript{3.0} (p=0.873), and TLG\textsubscript{6/14} (p=0.873) were not significant predictors of progression or death at 3 years.

**3. Prognostic factors and survival analyses**

![Fig. 1. Time-dependent ROC curve analyses for determination of the cutoff values of SUV\textsubscript{max}, MTV\textsubscript{2.5}, and TLG\textsubscript{2.5} for predicting 3-year progression (A) and death (B). AUC, area under the curve; MTV, metabolic tumor volume; ROC, receiver operating characteristic; SUV\textsubscript{max}, maximum standardized uptake value; TLG, total lesion glycolysis.](https://ejgo.org)
Table 3. Univariate and multivariate analyses of prognostic factors for PFS and OS in patients with UCS

| Characteristics | PFS HR (95% CI) p | OS HR (95% CI) p |
|-----------------|------------------|-----------------|
| **Univariate analysis** | | |
| Age (yr) | Continuous | 1.023 (0.971–1.077) | 0.397 | 1.019 (0.966–1.076) | 0.487 |
| Preoperative CA-125 (U/mL) | ≥35 vs. <35 | 1.632 (0.719–3.702) | 0.241 | 1.642 (0.695–3.896) | 0.260 |
| FIGO stage | III–IV vs. I–II | 3.206 (1.338–7.682) | 0.009 | 2.538 (1.068–6.029) | 0.035 |
| Tumor diameter (cm) | Continuous | 1.170 (1.068–1.281) | 0.001 | 1.186 (1.070–1.314) | 0.001 |
| ≥6 vs. <6 | | 5.547 (2.061–14.934) | 0.001 | 4.447 (1.647–12.009) | 0.003 |
| Histology | Heterologous vs. homologous | 3.731 (1.599–8.703) | 0.002 | 2.940 (1.252–6.907) | 0.011 |
| Lymphovascular space invasion | Present vs. absent | 1.912 (0.853–4.286) | 0.116 | 1.468 (0.637–3.383) | 0.368 |
| Myometrial invasion | ≥50% vs. <50% | 3.231 (1.346–7.756) | 0.009 | 3.520 (1.712–11.121) | 0.006 |
| Cervical stromal invasion | Present vs. absent | 2.999 (1.358–6.625) | 0.007 | 2.911 (1.279–6.626) | 0.011 |
| Adnexal invasion | Present vs. absent | 3.328 (1.449–7.641) | 0.005 | 3.649 (1.448–9.200) | 0.006 |
| PALN or PLN metastasis | Present vs. absent | 2.301 (1.049–5.050) | 0.038 | 1.720 (0.769–3.843) | 0.017 |
| Peritoneal cytology | Malignant vs. benign | 4.901 (2.137–11.242) | <0.001 | 4.414 (1.789–10.891) | 0.001 |
| SUV<sub>max</sub> | Continuous | 0.993 (0.908–1.085) | 0.873 | 1.006 (0.908–1.114) | 0.913 |
| ≥33 vs. <33 | | 1.930 (0.793–4.707) | 0.148 | 1.979 (0.774–5.060) | 0.154 |
| MTV<sub>2.5</sub> (mL) | Continuous | 1.001 (1.000–1.003) | 0.070 | 1.002 (1.001–1.004) | 0.008 |
| ≥63.92 vs. <63.92 | | 3.264 (1.486–7.268) | 0.004 | 2.764 (1.217–6.274) | 0.015 |
| TLG<sub>2.5</sub> (g) | Continuous | 1.000 (1.000–1.001) | 0.087 | 1.001 (1.000–1.002) | 0.016 |
| ≥396.16 vs. <396.16 | | 2.692 (1.224–5.924) | 0.014 | 2.721 (1.198–6.182) | 0.077 |
| MTV<sub>2.5</sub> (mL) | Continuous | 1.002 (1.000–1.005) | 0.079 | 1.003 (1.000–1.008) | 0.027 |
| ≥56.78 vs. <56.78 | | 3.264 (1.466–7.286) | 0.004 | 2.764 (1.217–6.274) | 0.015 |
| TLG<sub>2.5</sub> (g) | Continuous | 1.000 (1.000–1.001) | 0.158 | 1.001 (1.000–1.001) | 0.050 |
| ≥183.45 vs. <183.45 | | 2.793 (1.231–6.335) | 0.014 | 2.412 (1.047–5.555) | 0.039 |
| Multivariate analysis† | | | |
| Peritoneal cytology | Malignant vs. benign | 6.039 (2.497–14.605) | <0.001 | 3.054 (1.184–7.874) | 0.021 |
| Histology | Heterologous vs. homologous | 4.363 (1.712–11.121) | 0.002 | 3.288 (1.057–10.226) | 0.040 |
| Tumor diameter (cm) | ≥6 vs. <6 | | | |

CA-125, cancer antigen 125; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; MTV, metabolic tumor volume; OS, overall survival; PALN, para-aortic lymph node; PFS, progression-free survival; PLN, pelvic lymph node; SUV<sub>max</sub>, maximum standardized uptake value; TLG, total lesion glycolysis; UCS, uterine carcinosarcoma.

†Because the optimal cutoff values of tumor size for predicting progression and death at 3 years were different as 5.5 cm and 6.5 cm, we used the mean value of them; "TLG was not incorporated in multivariate analysis because of the strong correlation between MTV and TLG (Spearman r=0.987, p<0.001), and MTV<sub>2.5</sub> and TLG<sub>2.5</sub> (Spearman r=0.998, p<0.001), respectively.

and TLG<sub>2.5</sub> (p=0.087) were not significant prognostic predictors of PFS. MTV<sub>2.5</sub> (p=0.008) and TLG<sub>2.5</sub> (p=0.016) were significant prognostic predictors of OS, whereas SUV<sub>max</sub> (p=0.913) was not. Using the abovementioned optimal cutoff values of SUV<sub>max</sub>, MTV<sub>2.5</sub>, and TLG<sub>2.5</sub> HRs for progression were 1.930 (95% CI=0.793–4.701; p=0.148), 3.264 mL (95% CI=1.466–7.268; p=0.004), and 2.692 g (95% CI=1.224–5.924; p=0.014), respectively. HRs for death using the same cutoff values for SUV<sub>max</sub>, MTV<sub>2.5</sub>, and TLG<sub>2.5</sub> were also shown in Table 3.

By multivariate Cox proportional hazard analysis, malignant peritoneal cytology (HR=6.039; 95% CI=2.497–14.605; p=0.001) and heterologous histology (HR=4.363; 95% CI=1.712–11.121; p=0.002) were independent prognostic factors for PFS, whereas malignant peritoneal cytology (HR=3.054; 95% CI=1.184–7.874; p=0.021) and tumor diameter of ≥6 cm (HR=3.288; 95% CI=1.057–10.226; p=0.040) were independent prognostic factors for OS.

Using the cutoff values to compare low vs. high SUV<sub>max</sub>, MTV<sub>2.5</sub>, and TLG<sub>2.5</sub> estimated 3-year PFS rates in patients were 70.8% vs. 46.4% (p=0.141), 76.8% vs. 25.3% (p=0.002), and 73.4% vs. 27.5% (p=0.011), respectively. Similarly, the 3-year OS rates in patients with low vs. high SUV<sub>max</sub>, MTV<sub>2.5</sub>, and TLG<sub>2.5</sub> were 71.4% vs. 45.6% (p=0.147), 71.0% vs. 31.3% (p=0.011), and 73.0% vs. 31.3% (p=0.011), respectively.

https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43
70.9% vs. 31.7% (p=0.013), respectively. Kaplan-Meier survival plots showed differences in PFS and OS according to the cutoff value of SUV\textsubscript{max}, MTV\textsubscript{2.5}, and TLG\textsubscript{2.5} (Fig. 2), MTV\textsubscript{3.0} and TLG\textsubscript{3.0} (Supplementary Fig. 2).

**Fig. 2.** Kaplan-Meier survival plots of PFS (A-C) and OS (D-F) according to SUV\textsubscript{max}, MTV\textsubscript{2.5}, and TLG\textsubscript{2.5}. MTV, metabolic tumor volume; OS, overall survival; PFS, progression-free survival; SUV\textsubscript{max}, maximum standardized uptake value; TLG, total lesion glycolysis.
4. Metabolic parameters of $^{18}$F-FDG PET/CT in relation to various clinicopathological parameters

SUV\textsubscript{max} was normally distributed; however, MTV and TLG values were not. Student’s t-test showed that the mean SUV\textsubscript{max} was not significantly different among all subgroups of clinicopathological parameters. Mann-Whitney U test determined that the mean ranks of both MTV\textsubscript{2.5} and TLG\textsubscript{2.5} were significantly different when patients were stratified according to the preoperative CA-125 level, FIGO stage, tumor diameter, histology, lymphovascular space invasion, myometrial invasion, and adnexal invasion but were not significantly different when they were stratified based on cervical stromal invasion, pelvic or para-aortic LN metastasis, or peritoneal cytology (Table 4).

DISCUSSION

This study suggests that MTV and TLG are more suitable as prognostic indicators than SUV\textsubscript{max} in patients with UCS. Furthermore, they were well correlated with clinicopathological prognostic factors.

---

Table 4. $^{18}$F-FDG PET/CT parameters of primary UCS in relation to various clinicopathological features

| Variable                        | No. (%) | SUV\textsubscript{max} | MTV\textsubscript{2.5} | TLG\textsubscript{2.5} | MTV\textsubscript{3.0} | TLG\textsubscript{3.0} |
|---------------------------------|---------|-------------------------|------------------------|------------------------|------------------------|------------------------|
|                                 |         | Mean±SD                 | Mean±SD                | Mean±SD                | Mean±SD                | Mean±SD                |
|                                 |         | p                       | p                      | p                      | p                      | p                      |
| Preoperative CA-125 (U/mL)      |         | 0.898                   | 0.010                  | 0.022                  | 0.007                  | 0.033                  |
| <35                             | 37 (69.8)| 9.7±4.8                 | 90.6±75.4              | 356.3±532.2            | 53.5±78.0              | 274.5±381.6            |
| ≥35                             | 16 (30.2)| 9.8±2.3                 | 161.6±163.3            | 722.0±788.1            | 129.5±139.9            | 627.4±728.3            |
| FIGO stage                      |         | 0.818                   | 0.005                  | 0.007                  | 0.006                  | 0.008                  |
| I–II                            | 24 (43.6)| 9.4±5.4                 | 41.4±47.0              | 191.4±205.5            | 32.2±36.3              | 165.8±179.3            |
| III–IV                          | 31 (56.4)| 9.7±3.1                 | 168.1±210.5            | 687.4±760.9            | 112.2±126.6            | 654.6±640.0            |
| Tumor diameter (cm)             |         | 0.248                   | <0.001                 | <0.001                 | <0.001                 | <0.001                 |
| <6                              | 25 (45.5)| 8.8±5.3                 | 16.1±15.0              | 77.5±73.4              | 12.6±11.8              | 68.1±66.1              |
| ≥6                              | 30 (54.5)| 10.2±3.0                | 193.4±200.2            | 798.8±705.7            | 131.2±117.7            | 648.9±597.9            |
| Histology                       |         | 0.688                   | <0.001                 | <0.001                 | <0.001                 | <0.001                 |
| Homologous                      | 31 (56.4)| 9.4±5.0                 | 57.3±120.6             | 268.9±574.1            | 47.2±103.6             | 238.2±528.2            |
| Heterologous                    | 24 (43.6)| 9.8±3.1                 | 184.5±202.3            | 731.9±621.4            | 116.1±95.8             | 574.4±474.2            |
| Lymphovascular space invasion   |         | 0.240                   | 0.009                  | 0.011                  | 0.017                  | 0.012                  |
| Absent                          | 30 (54.5)| 9.0±4.7                 | 73.4±119.4             | 312.8±466.6            | 57.0±90.5              | 265.3±389.4            |
| Present                         | 25 (45.5)| 10.3±3.4                | 160.2±212.2            | 660.7±755.7            | 101.6±117.7            | 528.4±636.8            |
| Myometrial invasion (%)         |         | 0.879                   | 0.004                  | 0.004                  | 0.006                  | 0.012                  |
| ≤50                             | 25 (45.5)| 9.5±5.3                 | 53.0±81.3              | 246.9±366.9            | 43.5±64.7              | 225.0±324.0            |
| >50                             | 30 (54.5)| 9.7±3.0                 | 162.7±209.6            | 657.7±745.9            | 106.8±123.4            | 525.6±624.3            |
| Cervical stromal invasion       |         | 0.358                   | 0.088                  | 0.113                  | 0.085                  | 0.082                  |
| Absent                          | 32 (58.2)| 9.8±4.9                 | 108.7±204.3            | 471.4±718.8            | 67.1±114.4             | 339.3±594.6            |
| Present                         | 23 (41.8)| 9.2±3.2                 | 118.3±124.8            | 521.9±524.7            | 90.0±94.7              | 442.2±442.9            |
| Adnexal invasion                |         | 0.172                   | 0.041                  | 0.036                  | 0.047                  | 0.059                  |
| Absent                          | 40 (72.7)| 9.1±4.4                 | 86.8±136.0             | 384.6±602.0            | 67.9±111.0             | 332.0±535.3            |
| Present                         | 15 (27.3)| 10.8±3.3                | 182.3±235.3            | 701.2±678.4            | 102.1±86.2             | 526.0±499.0            |
| Pelvic or para-aortic LN metastasis | 0.823      | 0.055                   | 0.083                  | 0.096                  | 0.062                  |
| Absent                          | 31 (56.4)| 9.5±4.9                 | 69.8±92.6              | 312.2±398.1            | 54.1±70.0              | 265.9±339.3            |
| Present                         | 24 (43.6)| 9.7±3.2                 | 168.3±229.2            | 675.9±810.9            | 107.2±133.8            | 538.6±679.2            |
| Peritoneal cytology             |         | 0.624                   | 0.059                  | 0.054                  | 0.038                  | 0.054                  |
| Benign                          | 35 (68.6)| 9.6±4.7                 | 95.6±171.7             | 366.8±484.2            | 57.5±74.0              | 285.5±353.2            |
| Malignant                       | 16 (31.4)| 10.3±2.8                | 169.8±181.8            | 776.8±863.5            | 132.7±148.6            | 663.5±766.3            

CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; MTV, metabolic tumor volume; SD, standard deviation; SUV\textsubscript{max}, maximum standardized uptake value; TLG, total lesion glycolysis; UCS, uterine carcinosarcoma.

*Statistical significance test was done by Student’s t-test; †Statistical significance test was done by Mann-Whitney U test.
Most previously published studies investigating the prognostic role of 18\textsuperscript{F}-FDG PET/CT in endometrial cancers included only a small percentage (0%–14.3%) of patients with UCS, and the most common histology was an endometrioid adenocarcinoma [14,19-24]. High SUV\textsubscript{max} of primary endometrial cancer showed significantly worse disease-free survival (DFS) or OS rates than those with a low SUV\textsubscript{max} [20-22]. Moreover, SUV\textsubscript{max} of primary endometrial cancer showed a significant correlation with clinicopathological prognostic factors [12,20,21,24].

In contrast, our study showed that SUV\textsubscript{max} of primary UCS was not associated with PFS or OS and was not correlated with clinicopathological prognostic factors. As an indicator of the single maximum voxel value in a tumor, SUV\textsubscript{max} may not represent the metabolic burden of the entire tumor, particularly in a nonhomogeneous tumor such as UCS. Moreover, SUV\textsubscript{max} can also be confounded by noise and tumor volume [25,26].

Compared to SUV\textsubscript{max}, MTV, and TLG of primary endometrial cancer were reported as more accurate parameters for categorizing high- and low-risk groups and are better correlated with clinicopathological features [14,27]. Our current study also showed that MTV and TLG were correlated with poor prognostic factors for UCS. Further, MTV and TLG of primary endometrial cancer were reported as independent prognostic factors for DFS or PFS [19,23]. Total body MTV was also a significant prognostic factor for OS in patients with stage IVB endometrial cancer [28]. In contrast to SUV\textsubscript{max}, volume-based parameters such as MTV and TLG represent metabolic activity of the entire tumor above a minimal threshold, which may reflect the overall tumor burden and behavior more accurately than SUV\textsubscript{max} [29]. These might also partially explain the better correlation of these volume-based metabolic parameters with clinicopathological prognostic factors than SUV\textsubscript{max} in the present study.

In a recent study analyzing a small number of UCS patients (n=28) during a median follow-up period of 18.6 months, cumulative TLG was the only independent risk factor for recurrence (HR=115.261; 95% CI=1.041–12,765.483; p=0.048) in patients with UCS, and PFS was significantly differed between high and low TLG groups (p=0.007, log-rank test) [16]. In contrast, MTV and TLG were not independent prognostic variables in present study though low MTV or TLG groups showed significantly prolonged survival compared to high groups (Fig. 2, Supplementary Fig. 2). We think that these discrepancies of results occurred by differences in variables used in statistics. Sum of all MTVs and cumulative TLG in a patient were analyzed as volumetric parameters in previous study [16], whereas MTV and TLG of primary uterine tumor were analyzed in present study. And 3 potential independent risk factors identified in this study were not incorporated as variables in multivariate analysis. Considering that peritoneal cytology, histology, and tumor diameter were independent prognostic factors, MTV and TLG could not entirely substitute for surgical staging. However, they may provide additional information for risk group stratification and survival prediction especially in patients who are not candidates for surgical staging, aiding in predicting patient outcomes, choosing the best treatment strategy.

There are currently several methods to delineate tumor volume in 18\textsuperscript{F}-FDG PET/CT, including manual drawing and automatic and semiautomatic methods using an isocontour threshold based on a fixed SUV\textsubscript{max} percentage, a specific SUV (e.g., 2.5 and 3.0), or a background-level threshold [28,30]; however, there is currently no consensus on the best method [31]. In our study, we selected VOIs based on fixed arbitrary SUV thresholds of 2.5 and 3.0 which were commonly used for other malignancies [18,19,32,33]. Previous studies showed that the clinical value of MTV and TLG might not be affected by specific tumor delineation methods, despite their significant impact on the absolute value of PET parameters [31,34,35].
Likewise, our results were not likely confounded by the chosen tumor delineation method. The HRs of MTV\textsubscript{3.0} and TLG\textsubscript{3.0} were similar to those of MTV\textsubscript{2.5} and TLG\textsubscript{2.5}, respectively, in univariate analyses, and the results of multivariate analysis were not changed. However, further studies are needed to determine standard methods and adequate cutoff values of tumor volume measurement with external validation before the utilization of our findings in clinical practice.

Our study has several limitations. First, this was a retrospective, single-center study with a small number of patients and short follow-up periods. However, considering the extreme rarity of UCS and poor oncologic outcomes, our study could provide meaningful information. Second, various adjuvant treatment modalities in our cohort could have affected the oncological outcomes. If indicated, all patients were recommended to receive adjuvant therapy, according to international guidelines [36]. As a result, majority of the patients (83.6\%, 46/55) received adjuvant therapy, except for 3 patients who refused treatment due to their personal preference or poor general condition. However, optimal therapy for UCS is still debated, and neither adjuvant radiotherapy nor chemotherapy was a significant prognostic factor for PFS or OS in prospective randomized trials [4]. Thus, any potential differences in adjuvant therapy were unlikely to impact our findings. Third, metabolic parameters of UCS are not completely separated from the physiologic uptake of endometrium [37] or post-biopsy change. In the present study, most study participants (94.5\%, 52/55) were postmenopausal, and the median time interval between endometrial biopsy and \textsuperscript{18}F-FDG PET/CT was 14 (0–43) days. While we could exclude the premenopausal physiologic uptake in most cases, we still cannot determine the contribution of post-biopsy change. We checked the correlation between PET parameters and interval between biopsy and FDG PET/CT, and we could not find any correlation between them. Finally, during the 10-year span of this study, 6 different PET scanners were used, which might have affected the \textsuperscript{18}F-FDG PET/CT parameters. To minimize impact, the first priority was given to compatibility with previous scanners when scanner-specific parameters such as voxel size and acquisition time per bed were set. Further prospective studies with a larger number of patients and longer follow-up periods are required to confirm our findings.

In conclusion, MTV and TLG of primary UCS were significant prognostic factors for predicting PFS and OS in univariate analysis and that they were correlated with clinicopathological prognostic factors. In contrast, SUV\textsubscript{max} was neither associated with PFS and OS nor correlated with clinicopathological features. MTV and TLG determined by \textsuperscript{18}F-FDG PET/CT may help in stratifying high-risk patients and predicting prognosis especially in patients who are not candidates for primary surgery.

SUPPLEMENTARY MATERIALS

Supplementary Fig. 1
Time-dependent ROC curve analyses for determination of the cutoff values of SUV\textsubscript{max}, MTV\textsubscript{3.0}, and TLG\textsubscript{3.0} for predicting 3-year progression (A) and death (B).

ROC, receiver operating characteristic; MTV, metabolic tumor volume; SUV\textsubscript{max}, maximum standardized uptake value; TLG, total lesion glycolysis.

Click here to view
Supplementary Fig. 2
Kaplan-Meier survival plots of PFS (A, B) and OS (C, D) according to MTV_{3.0} and TLG_{3.0}.

MTV, metabolic tumor volume; OS, overall survival; PFS, progression-free survival; SUV_{max}, maximum standardized uptake value; TLG, total lesion glycolysis.

Click here to view

REFERENCES

1. Guarino M, Giordano F, Pallotti F, Polizzotti G, Tricomi P, Cristofori E. Malignant mixed müllerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis. Tumori 1998;84:391-7.

2. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90.

3. Artioli G, Wabersich J, Ludwig K, Gardiman MP, Borgato L, Garbin F. Rare uterine cancer: carcinosarcomas. Review from histology to treatment. Crit Rev Oncol Hematol 2015;94:98-104.

4. Cantrell LA, Blank SW, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 2015;137:581-8.

5. George E, Lillemoe TJ, Twigg LS, Perrone T. Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.

6. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, et al. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Int J Clin Oncol 2016;21:168-76.

7. Zhu J, Wen H, Bi R, Wu X. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. J Gynecol Oncol 2016;27:e18.

8. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008;111:82-8.

9. Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer 2011;21:877-84.

10. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782-6.

11. Gunogordok K, Ozdemir A, Ertas IE, Gokcu M, Telli E, Oge T, et al. Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas. Cancer Res Treat 2015;47:282-9.

12. Walentowicz-Sadlecka M, Malkowski B, Walentowicz P, Sadlecki P, Marszalek A, Pietrzak T, et al. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients. Biomed Res Int 2014;2014:234813.

13. Tsujikawa T, Yoshida Y, Kudo T, Kiyono Y, Kurokawa T, Kobayashi M, et al. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. J Nucl Med 2009;50:1598-604.
14. Kitajima K, Suenaga Y, Ueno Y, Maeda T, Ebina Y, Yamada H, et al. Preoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancer. Eur J Nucl Med Mol Imaging 2015;42:1268-75.

15. Ho KC, Lai CH, Wu TJ, Ng KK, Yen TC, Lin G, et al. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging 2008;35:484-92.

16. Lee JW, Heo EJ, Moon SH, Lee H, Cheon GI, Lee M, et al. Prognostic value of total lesion glycolysis on preoperative (18)F-FDG PET/CT in patients with uterine carcinosarcoma. Eur Radiol 2016;26:4148-54.

17. Lee HJ, Park JY, Lee JJ, Kim MH, Kim DY, Suh DS, et al. Comparison of MRI and 18F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. Gynecol Oncol 2016;140:409-14.

18. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 2007;67:720-6.

19. Shim SH, Kim DY, Lee DY, Lee SW, Park JY, Lee JJ, et al. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer. BJOG 2014;121:1097-106.

20. Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer. Gynecol Oncol 2011;123:82-7.

21. Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging 2012;39:840-5.

22. Kim HJ, Choi J, Jeong YH, Jo KH, Lee JH, Cho A, et al. Prognostic value of metabolic activity measured by (18)F-FDG PET/CT in patients with advanced endometrial cancer. Nucl Med Mol Imaging 2013;47:257-62.

23. Chung HH, Lee I, Kim HS, Kim JW, Park NH, Song YS, et al. Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer. Gynecol Oncol 2013;130:446-51.

24. Lee HJ, Ahn BC, Hong CM, Song BI, Kim HW, Kang S, et al. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer. Nucl Instr Meth B 2011;50:204-13.

25. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45.

26. Kim HS, Choi JY, Choi DW, Lim HY, Lee JH, Hong SP, et al. Prognostic value of volume-based metabolic parameters measured by (18)F-FDG PET/CT of pancreatic neuroendocrine tumors. Nucl Med Mol Imaging 2014;48:180-6.

27. Husby JA, Reitan BC, Biermann M, Trovik J, Bjørge L, Magnussen II, et al. Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. J Nucl Med 2015;56:1193-8.

28. Liu FJ, Chao A, Lai CH, Chou HH, Yen TC. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol 2012;125:566-71.

29. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 2012;19:1966-72.

30. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-130S.
31. Moon SH, Choi JY, Lee HI, Son YI, Back CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck 2013;35:15-22.

32. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:353-9.

33. Chung MK, Jeong HS, Son YI, So YK, Park GY, Choi JY, et al. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol 2009;16:3111-7.

34. Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol 2013;14:142.

35. Kim K, Kim SJ, Kim JJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun 2012;33:613-20.

36. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw 2014;12:248-80.

37. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266-71.